Cargando…
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
This analysis provides a comprehensive clinical assessment of the long-term safety of the licensed dose of olodaterol (5 µg once daily [QD] via Respimat(®) inhaler) in patients with chronic obstructive pulmonary disease by exploring the occurrence of acknowledged side effects of long-acting β(2)-ago...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653794/ https://www.ncbi.nlm.nih.gov/pubmed/29061968 http://dx.doi.org/10.1038/s41533-017-0059-1 |